Addendum
Isatuximab (multiple myeloma after >= 1 prior therapy, combination with carfilzomib and dexamethasone) - Addendum to Commission A21-60
Report documents
-
Addendum
Isatuximab (multiple myeloma after >= 1 prior therapy, combination with carfilzomib and dexamethasone) - Addendum to Commission A21-60
Dossier assessment
Indication:
Adult patients with multiple myeloma who have received at least one prior therapy
Result of dossier assessment:
Unchanged after addendum: Added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2021-11-04 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A21-123
- Commission
- Commission awarded on 30.09.2021 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Isatuximab (multiple myeloma after >= 1 prior therapy, combination with carfilzomib und dexamethasone) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed